IP Library Granted Patent US 8,236,558
Granted Patent B2
US 8,236,558 · App. 12/871,902 · Granted Aug 7, 2012

Bovine immunodeficiency virus (BIV) based vectors

Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,236,558
App. No.
12/871,902
Granted
Aug 7, 2012
Kind
B2
Abstract

BIV packaging constructs, BIV packaging cell lines, methods of making BIV packaging cells and methods of making BIV producer cells are described.

Claims (16)

1. A bovine immunodeficiency virus (BIV) packaging construct comprising a BIV DNA sequence fragment comprising at least a gag or a pol gene of BIV, and a promoter operably linked to said BIV DNA fragment.

2. The BIV construct of claim 1 further comprising an internal ribosome binding site.

3. The BIV construct of claim 1 further comprising a heterologous intron.

4. A BIV packaging cell line comprising an established cell line transformed by the BIV construct of claim 1 .

5. A packaging construct comprising a promoter operatively linked to a BIV gag/pol coding sequence and a polyadenylation signal at the 3′ end of said gag/pol coding sequence.

6. The packaging construct of claim 5 , further comprising an intron upstream of said gag/pol coding sequence.

7. The packaging construct of claim 5 , further comprising an RNA transport element.

8. The packaging construct of claim 7 , wherein said RNA transport element comprises a lentiviral rev response element (RRE).

9. The packaging construct of claim 8 , wherein said lentiviral RRE comprises a BIV RRE.

10. The packaging construct of claim 7 , wherein said RNA transport element comprises a constitutive transport element (CTE).

11. The packaging construct of claim 10 , wherein said CTE is a Mason-Pfizer monkey virus CTE.

12. The packaging construct of claim 8 , further comprising a Rev coding sequence.

13. A method of making a packaging cell comprising the steps of (1) transfecting a cell with a BIV gag/pol coding sequence and (2) transfecting the cell with a viral envelope coding sequence.

14. The method of claim 13 , wherein said cell is a mammalian cell.

15. The method of claim 14 , wherein said mammalian cell is a human cell.

16. A method of making a producer cell comprising transfecting the packaging cell of claim 13 with a transfer vector comprising a transgene.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT OPHTHALMICS CORPORATION
Reel/Frame 054983/0577 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0182 →
SECURITY AGREEMENT Recorded Aug 15, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031030/0720 →
Continuity (5)
Division 11076399 · Mar 8, 2005
Division 09734836 · Dec 12, 2000
Provisional Application 60249492 · Nov 17, 2000
Provisional Application 60266318 · Dec 14, 1999
Related Publication 20110171733A1 · Jul 14, 2011